e-Library : Publications
Rss18 Apr 2013
Guidance for Manufacturers : What is required to be ready to connect to the EMVS?
Topics:
18 Apr 2013
Topics:
18 Apr 2013
Topics:
11 Mar 2013
24 Jan 2013
Between
Topics:
8 Jan 2013
Tags: Animals, Research & Innovation, Publications
This report actually offers you the best of both worlds as it is produced in an interactive pdf format which can be used just like any normal pdf, and it is therefore easy to print and read like a brochure; but if you are using it online or on a
Topics:
Pharmaceutical Industry R&D for Diseases of the Developing World November 2011 (IFPMA Status Report)
4 Sep 2012
This document lists research-based pharmaceutical company(1) projects(2) to develop new medicines and vaccines for the ten diseases of the developing world (DDW) prioritized by the Programme for Research and Training in Tropical Diseases (TDR),
Topics:
26 Jun 2012
Tags: Development of Medicines, Patients’ Access to Medicines, Research & Innovation, Responsible Industry, Value of the Industry, Publications
26 Jun 2012
As in previous years, EPAA has brought experts and practitioners together from across the widest spectrum of stakeholders to seek new insights and achievements.
23 Jun 2012
The research-based pharmaceutical industry can play a critical role in restoring Europe to growth. In 2011 it invested an estimated 27,500 million in R&D in Europe.
Topics:
23 Jun 2012
Tags: Access, Anti-Counterfeiting, ESM, Falsified medicines, Patients’ Access to Medicines, Serialisation, Publications
A genuine threat to public health
Over 30 million counterfeit medicines have been seized by customs at EU borders over the last five years1
Counterfeiters do not discriminate between branded or generic medicines.
Topics:
13 May 2011
Over the last ten years, Health Technology Assessment (HTA) has become an increasingly important part of the assessment system for new medicines.
28 Nov 2010
Tags: Access, Global health, Healthcare systems, Patient, Patients’ Access to Medicines, Pricing, Regulation, Reimbursement, Responsible Industry, Value of the Industry, Publications
The latest edition shows that, depending on the patients' country of residence, doctors would be able to prescribe between 39% and 86% of the new medicines with a valid EU marketing authorisation granted between 1 January 2007 and 31 December 20
14 June 2011, EFPIA's General Assembly has approved the amended EFPIA Code of Practice on relationships between the pharmaceutical industry and patient organisations which is effective from 1 January
Topics:
14 June 2011, EFPIA's General Assembly has approved the amended Code of Practice on the promotion of prescription-only medicines to, and interactions with, healthcare professionals.
The amended code is effective from 1 January 2012.
Topics:
Every new medicine is the result of a long, painstaking and costly research and development process. Thousands of compounds are tested but very few survive the rigorous testing process. That process and the products it produces must have... more
Topics:
Tags: Animals, CSR, Development of Medicines, Innovation, Research, Research & Innovation, Responsible Industry, Publications
De medische research gaat snel vooruit, maar er liggen nog veel uitdagingen in het verschiet.
Tags: Animals, Development of Medicines, Innovation, Research, Research & Innovation, Responsible Industry, Publications
La recherche médicale progresse rapidement, révélant dans la foulée de nombreux nouveaux défis en matière de santé.
Tags: Animals, Development of Medicines, Innovation, Research & Innovation, Responsible Industry, Publications
The pace of medical research is fast, but there are still many health challenges ahead.
Tags: Development of Medicines, Patients’ Access to Medicines, Research & Innovation, Responsible Industry, Value of the Industry, Publications
Europe has a great deal to gain in health and economic terms from a strong and competitive indigenous research-based pharmaceutical sector.